HLA Class I and II Expression in Oropharyngeal Squamous Cell Carcinoma in Relation to Tumor HPV Status and Clinical Outcome

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Näsman, Anders ^a   Andersson, Emilia ^a   Marklund, Linda ^b   Tertipis, Nikolaos ^a   Hammarstedt Nordenvall, Lalle ^b   Attner, Per ^b   Nyberg, Tommy ^a   Masucci, Giuseppe V ^a   Munck Wikland, Eva ^b   Ramqvist, Torbjörn ^a   Dalianis, Tina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOCETAXEL; FLUOROURACIL; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; VIRUS DNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SQUAMOUS CELL CARCINOMA; SWEDEN; TREATMENT RESPONSE; TUMOR BIOPSY; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84885396468     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077025     Document Type: Article

References (43)

1. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, et al. (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29: 4294-4301. doi:10.1200/JCO.2011.36.4596. PubMed: 21969503.
2. Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, et al. (2009) Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 125: 362-366. doi:10.1002/ijc.24339. PubMed: 19330833.
3. Blomberg M, Nielsen A, Munk C, Kjaer SK, (2011) Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer 129: 733-741. doi:10.1002/ijc.25699. PubMed: 20878955.
4. Braakhuis BJ, Visser O, Leemans CR, (2009) Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol 45: e85-e89. doi:10.1016/j.oraloncology.2008.02.011. PubMed: 19457708.
5. de Camargo Cancela M, de Souza DL, Curado MP, (2012) International incidence of oropharyngeal cancer: a population-based study. Oral Oncol 48: 484-490. doi:10.1016/j.oraloncology.2011.12.013. PubMed: 22265333.
6. Dahlstrand H, Näsman A, Romanitan M, Lindquist D, Ramqvist T, et al. (2008) Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer. Anticancer Res 28: 1133-1138. PubMed: 18505048.
7. Ragin CC, Taioli E, (2007) Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 121: 1813-1820. doi:10.1002/ijc.22851. PubMed: 17546592.
8. Lindquist D, Romanitan M, Hammarstedt L, Näsman A, Dahlstrand H, et al. (2007) Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 1: 350-355. doi:10.1016/j.molonc.2007.08.005. PubMed: 19383307.
9. Chung CH, Schwartz DL, (2012) Impact of HPV-related head and neck cancer in clinical trials: opportunity to translate scientific insight into personalized care. Otolaryngol Clin North Am 45: 795-806. doi:10.1016/j.otc.2012.04.002. PubMed: 22793853.
10. Pryor DI, Solomon B, Porceddu SV, (2011) The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. Asia Pac J Clin Oncol 7: 236-251. doi:10.1111/j.1743-7563.2011.01420.x. PubMed: 21884435.
11. Gillison ML, (2004) Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31: 744-754. doi:10.1053/j.seminoncol.2004.09.011. PubMed: 15599852.
12. Lewis JS Jr., (2012) p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 6 (Suppl 1):: S75-S82. doi:10.1007/s12105-012-0336-9. PubMed: 22782226.
13. Näsman A, Andersson E, Nordfors C, Grün N, Johansson H, et al. (2013) MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome. Int J Cancer 132: 72-81. doi:10.1002/ijc.27635. PubMed: 22592660.
14. Bottley G, Watherston OG, Hiew YL, Norrild B, Cook GP, et al. (2008) High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 27: 1794-1799. doi:10.1038/sj.onc.1210798. PubMed: 17828295.
15. Campo MS, Graham SV, Cortese MS, Ashrafi GH, Araibi EH, et al. (2010) HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407: 137-142. doi:10.1016/j.virol.2010.07.044. PubMed: 20813390.
16. Li H, Ou X, Xiong J, Wang T, (2006) HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter. Biochem Biophys Res Commun 349: 1315-1321. doi:10.1016/j.bbrc.2006.08.182. PubMed: 16979588.
17. Glew SS, Connor ME, Snijders PJ, Stanbridge CM, Buckley CH, et al. (1993) HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection. Eur J Cancer 29A: 1963-1970. PubMed: 8280490.
18. Zehbe I, Höhn H, Pilch H, Neukirch C, Freitag K, et al. (2005) Differential MHC class II component expression in HPV-positive cervical cancer cells: implication for immune surveillance. Int J Cancer 117: 807-815. doi:10.1002/ijc.21226. PubMed: 15981207.
19. Glew SS, Duggan-Keen M, Cabrera T, Stern PL, (1992) HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res 52: 4009-4016. PubMed: 1377602.
20. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S, (1997) Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci U S A 94: 6886-6891. doi:10.1073/pnas.94.13.6886. PubMed: 9192661.
21. Armstrong TD, Clements VK, Ostrand-Rosenberg S, (1998) MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J Immunol 160: 661-666. PubMed: 9551900.
22. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, et al. (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66: 6405-6411. doi:10.1158/0008-5472.CAN-06-0854. PubMed: 16778219.
23. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, et al. (1988) Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48: 1019-1025. PubMed: 3338074.
24. Matoba K, Iizuka N, Gondo T, Ishihara T, Yamada-Okabe H, et al. (2005) Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer 115: 231-240. doi:10.1002/ijc.20860. PubMed: 15688398.
25. Momburg F, Herrmann B, Moldenhauer G, Möller P, (1987) B-cell lymphomas of high-grade malignancy frequently lack HLA-DR,-DP and-DQ antigens and associated invariant chain. Int J Cancer 40: 598-603. doi:10.1002/ijc.2910400504. PubMed: 3316049.
26. Esteban F, Ruiz-Cabello F, Concha A, Pérez-Ayala M, Sánchez-Rozas JA, et al. (1990) HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clin Exp Metastasis 8: 319-328. doi:10.1007/BF01810678. PubMed: 2350918.
27. Ramqvist T, Du J, Lundén M, Ahrlund-Richter S, Ferreira J, et al. (2011) Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15-23-year-old women attending a youth health clinic in Stockholm, Sweden. Scand J Infect Dis 43: 115-121. doi:10.3109/00365548.2010.526957. PubMed: 20964488.
28. Hutter H, Hammer A, Blaschitz A, Hartmann M, Ebbesen P, et al. (1996) Expression of HLA class I molecules in human first trimester and term placenta trophoblast. Cell Tissue Res 286: 439-447. doi:10.1007/s004410050713. PubMed: 8929346.
29. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, et al. (2003) Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171: 1918-1926. PubMed: 12902494.
30. Grandea AG 3rd, Androlewicz MJ, Athwal RS, Geraghty DE, Spies T, (1995) Dependence of peptide binding by MHC class I molecules on their interaction with TAP. Science 270: 105-108. doi:10.1126/science.270.5233.105. PubMed: 7569935.
31. Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, et al. (1993) Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods 161: 239-256. doi:10.1016/0022-1759(93)90300-V. PubMed: 8505553.
32. Chiriva-Internati M, Grizzi F, Pinkston J, Morrow KJ, D'Cunha N, et al. (2006) Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim 42: 89-95. doi:10.1290/0508054.1. PubMed: 16759154.
33. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, et al. (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203: 1259-1271. doi:10.1084/jem.20052494. PubMed: 16636135.
34. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ, (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57: 197-206. PubMed: 17622526.
35. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG, (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117: 248-255. doi:10.1002/ijc.21163. PubMed: 15900607.
36. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, et al. (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26: 3128-3137. doi:10.1200/JCO.2007.12.7662. PubMed: 18474878.
37. Mellin Dahlstrand H, Lindquist D, Björnestål L, Ohlsson A, Dalianis T, et al. (2005) P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res 25: 4375-4383. PubMed: 16334111.
38. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, et al. (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35. doi:10.1056/NEJMoa0912217. PubMed: 20530316.
39. Marklund L, Näsman A, Ramqvist T, Dalianis T, Munck-Wikland E, et al. (2012) Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer. Cancer Med 1: 82-88. doi:10.1002/cam4.2. PubMed: 23342257.
40. Rocco JW, Sidransky D, (2001) p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 264: 42-55. doi:10.1006/excr.2000.5149. PubMed: 11237522.
41. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, et al. (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11: 2552-2560. doi:10.1158/1078-0432.CCR-04-2146. PubMed: 15814633.
42. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, et al. (2006) HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 66: 9281-9289. doi:10.1158/0008-5472.CAN-06-0488. PubMed: 16982773.
43. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, et al. (2012) Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 61: 1243-1253. doi:10.1007/s00262-012-1201-0. PubMed: 22258792.